Danielle Charpentier

Montreal, QC, CA 
Montreal, QC, CA 

Overview

Danielle Charpentier practices practicing medicine in Montreal, Canada.

Her clinical expertise encompasses Colorectal Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and COVID-19.

She is actively involved in clinical research, co-authoring 26 peer reviewed articles and participating in 4 clinical trials.

Gender

Female

Locations

Montreal, QC, Canada
Other Locations
Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
A Investigator Initiated Phase II Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
A Investigator Initiated Phase II Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Enrollment Status: Completed
Publish Date: October 17, 2024
Intervention Type: Drug
Study Drug: Sunitinib
Study Phase: Phase 2
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drugs: GSK525762, Fulvestrant
Study Phase: Phase 1
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
View 3 Less Clinical Trials

26 Total Publications

Phase I/II Trial of Durvalumab plus Tremelimumab and Stereotactic Body Radiotherapy for Metastatic Head and Neck Carcinoma.
Phase I/II Trial of Durvalumab plus Tremelimumab and Stereotactic Body Radiotherapy for Metastatic Head and Neck Carcinoma.
Journal: International journal of radiation oncology, biology, physics
Published: February 10, 2026

Frequently Asked Questions about Danielle Charpentier

Is Danielle Charpentier a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Danielle Charpentier is classified as an Experienced expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Danielle Charpentier participate in research or clinical trials?

Yes. Danielle Charpentier has published 26 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Danielle Charpentier's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Charpentier's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile